AstraZeneca: FDA approves new dosing for cancer drug Imfinzi
(CercleFinance.com) - AstraZeneca said on Friday that the US Food and Drug Administration has approved a four-week dosing schedule for its cancer drug Imfinzi.
Imfinzi in a two-week dosing schedule was previously approved to treat unresectable stage III non-small cell lung cancer after chemotherapy and previously treated advanced bladder cancer.
"This new four-week dosing option gives doctors the choice to cut the number of visits for critical cancer treatment in half and offers a regimen that is more convenient for patients," said Victoria Villaflor, an oncology professor at City of Hope Cancer Center in Los Angeles.
The physician said the approval also limits potential exposure to infection in the healthcare environment for a population that is especially vulnerable to complications from Covid-19.
The four-week option for Imfinzi is also under regulatory review in several other countries, including in the EU.
Imfinzi, a human monoclonal antibody, blocks the tumour's immune-evading tactics.
Copyright (c) 2020 CercleFinance.com. All rights reserved.
Imfinzi in a two-week dosing schedule was previously approved to treat unresectable stage III non-small cell lung cancer after chemotherapy and previously treated advanced bladder cancer.
"This new four-week dosing option gives doctors the choice to cut the number of visits for critical cancer treatment in half and offers a regimen that is more convenient for patients," said Victoria Villaflor, an oncology professor at City of Hope Cancer Center in Los Angeles.
The physician said the approval also limits potential exposure to infection in the healthcare environment for a population that is especially vulnerable to complications from Covid-19.
The four-week option for Imfinzi is also under regulatory review in several other countries, including in the EU.
Imfinzi, a human monoclonal antibody, blocks the tumour's immune-evading tactics.
Copyright (c) 2020 CercleFinance.com. All rights reserved.